Journal of Medical & Surgical Pathology
Open Access

Molecular Profiling of Metaplastic Carcinoma Variants

Lin Liang^{* *}Correspondence: Lin Liang, Departments of Pathology, University of Fudan, Shanghai, China, Email:

Author info »

Description

Metaplastic carcinoma of the breast represents a rare and heterogeneous group of malignant tumors characterized by the presence of both epithelial and mesenchymal components. Unlike conventional invasive ductal carcinomas, these tumors often exhibit differentiation into squamous, spindle, chondroid, or osseous elements, reflecting a high degree of cellular plasticity. The clinical behavior of metaplastic carcinomas is typically aggressive, with a propensity for early recurrence and resistance to conventional therapies. Understanding the molecular landscape of these tumors is essential for accurate diagnosis, prognostication, and the development of targeted therapeutic strategies. Molecular profiling provides insights into the genomic, transcriptomic, and epigenetic alterations that drive the phenotypic diversity of metaplastic carcinoma variants and underpins the heterogeneity observed in clinical outcomes.

The epithelial-mesenchymal transition is a key biological process implicated in the pathogenesis of metaplastic carcinoma. Tumor cells acquire mesenchymal characteristics, leading to the formation of spindle-shaped or sarcomatoid components. Molecular profiling has revealed that this transition is accompanied by alterations in genes regulating cell adhesion, cytoskeletal organization, and extracellular matrix interactions. For example, downregulation of E-cadherin and upregulation of vimentin are consistent features across many metaplastic carcinoma variants, reflecting loss of epithelial polarity and acquisition of invasive properties. These molecular changes not only influence tumor morphology but also correlate with higher tumor grade, increased mitotic activity, and enhanced metastatic potential.

Transcriptomic analyses have further delineated distinct molecular subtypes within metaplastic carcinoma. Tumors with squamous differentiation often demonstrate upregulation of genes associated with epidermal development, keratinization, and squamous morphogenesis. Spindle cell variants show enrichment of genes involved in extracellular matrix organization, cytoskeletal remodeling, and epithelialmesenchymal transition. Chondroid and osseous components express genes linked to cartilage and bone formation, including transcription factors regulating mesenchymal lineage commitment. These gene expression profiles correlate with histological features and provide a framework for understanding the diverse morphologies observed in metaplastic carcinoma. Importantly, these molecular signatures can inform the selection of targeted therapies and predict response to emerging agents.

Epigenetic alterations also contribute to the heterogeneity of metaplastic carcinoma. Deoxyribonucleic Acid (DNA) methylation patterns, histone modifications, and non-coding Ribonucleic Acid (RNA) expression influence gene expression programs that drive epithelial-mesenchymal transition and mesenchymal differentiation. For instance, hypermethylation of tumor suppressor gene promoters can result in loss of expression, facilitating tumor progression, while dysregulation of microRNAs involved in cell cycle control and apoptosis may promote chemoresistance. Epigenetic profiling, in combination with genomic and transcriptomic analyses, provides a comprehensive view of the molecular landscape and identifies potential biomarkers for diagnosis and therapy.

The tumor microenvironment plays a critical role in the behavior of metaplastic carcinoma. Molecular profiling has revealed interactions between tumor cells and surrounding stromal components, including fibroblasts, immune cells, and extracellular matrix proteins. Tumor-associated fibroblasts contribute to mesenchymal differentiation and facilitate invasion through secretion of growth factors and remodeling of the extracellular matrix. Immune profiling has demonstrated an immunosuppressive microenvironment characterized by regulatory T cell infiltration, macrophage polarization, and expression of immune checkpoint molecules. These findings suggest that metaplastic carcinomas may benefit from combination strategies that target both tumor-intrinsic pathways and the tumor microenvironment, including immune checkpoint inhibitors and stromal-targeted therapies.

Clinical studies have correlated molecular alterations with outcomes in patients with metaplastic carcinoma. These insights underscore the importance of individualized therapeutic strategies based on comprehensive molecular characterization. Despite advances in molecular profiling, challenges remain in translating these findings into clinical practice. The rarity and heterogeneity of metaplastic carcinoma limit the availability of large-scale studies, and the variable representation of different histological components within a single tumor complicates molecular analysis. Intra-tumoral heterogeneity can result in sampling bias, and the dynamic nature of epithelialmesenchymal transition may lead to temporal changes in gene expression and signaling pathways. Integration of multi-omic data with detailed histopathological evaluation is essential to accurately capture the complexity of metaplastic carcinoma and guide therapeutic decision-making.

Conclusion

Molecular profiling of metaplastic carcinoma variants provides critical insights into the biological mechanisms underlying tumor heterogeneity, aggressive behavior, and therapeutic resistance. Genomic, transcriptomic, and epigenetic analyses have delineated distinct molecular subtypes that correlate with histological features and clinical outcomes. The interplay between tumor-intrinsic alterations and the tumor microenvironment shapes tumor progression and influences response to therapy. Comprehensive molecular characterization has the potential to identify actionable targets, guide personalized treatment strategies, and improve prognosis in this challenging subset of breast cancers. Continued research integrating molecular profiling with clinical and histopathological data will be essential to advance understanding, refine risk stratification, and develop effective therapies for patients with metaplastic carcinoma.